High Dose Intravenous Busulfan and Melphalan Followed By Bortezomib (BuMelVel) As Conditioning With Autologous Stem Cell Transplantation (ASCT) For Patients With Multiple Myeloma (MM)

被引：0
|
作者：
Sterrenberg, Danielle
Stiff, Patrick J.
Parthasarathy, Mala
Go, Aileen
Smith, Scott E.
Rodriguez, Tulio E.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.3376.3376
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3376
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Toxicity and early response after single daily dose of intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    de la Rubia, J.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Sanz, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 192 - 192
  • [22] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Miyamoto, Toshihiro
    Yoshimoto, Goichi
    Kamimura, Tomohiko
    Muta, Tsuyoshi
    Takashima, Shuichiro
    Ito, Yoshikiyo
    Shiratsuchi, Motoaki
    Choi, Ilseung
    Kato, Koji
    Takenaka, Katsuto
    Iwasaki, Hiromi
    Takamatsu, Yasushi
    Teshima, Takanori
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 98 (03) : 337 - 345
  • [23] Combination of high-dose melphalan and bortezomib as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma
    Toshihiro Miyamoto
    Goichi Yoshimoto
    Tomohiko Kamimura
    Tsuyoshi Muta
    Shuichiro Takashima
    Yoshikiyo Ito
    Motoaki Shiratsuchi
    Ilseung Choi
    Koji Kato
    Katsuto Takenaka
    Hiromi Iwasaki
    Yasushi Takamatsu
    Takanori Teshima
    Koichi Akashi
    International Journal of Hematology, 2013, 98 : 337 - 345
  • [24] Feasibility of high dose busulfan and melphalan with autologous hematopoietic stem cell transplantation in multiple myeloma.
    Begum, U
    Fitzgerald, D
    Yong, LO
    Grand, M
    Thomas, U
    Chen, Y
    Patel, A
    Goodman, D
    Dillon, C
    Amorosi, E
    Cook, P
    BLOOD, 1997, 90 (10) : 4346 - 4346
  • [25] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    de Miguel, D.
    Morales, D.
    San Roman, I.
    Golbano, N.
    Diaz, M.
    Arbeteta, J.
    Herrero, S.
    Subira, D.
    PInedo, B.
    HAEMATOLOGICA, 2012, 97 : 622 - 622
  • [26] BORTEZOMIB WITH HIGH DOSE MELPHALAN CONDITIONING FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IS SAFE AND IMPROVES THE RESPONSE RATE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
    Dalla Palma, B.
    Prezioso, L.
    Accardi, F.
    Rossetti, E.
    Aversa, F.
    Giuliani, N.
    HAEMATOLOGICA, 2015, 100 : 160 - 160
  • [27] BORTEZOMIB AND HIGH-DOSE MELPHALAN AS CONDITIONING REGIMEN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: EXPERIENCE IN A UNIVERSITARY HOSPITAL
    Dunia, D. M.
    Dolores, M.
    Dolores, S.
    Nuria, G.
    Miguel, D.
    Jaime, A.
    Helga, G.
    Alejandro, V.
    Sonia, H.
    Blanca, P.
    HAEMATOLOGICA, 2016, 101 : 862 - 862
  • [28] Bortezomib after high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with multiple myeloma: A comparison with the historical conditioning regimen with melphalan alone
    Ferini, G. A.
    Arbelbide, J. A.
    Basquiera, A. L.
    Nucifora, E.
    Schutz, N.
    Otero, V.
    Fantl, D.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S461 - S462
  • [29] Autologous stem cell transplantation with high dose melphalan conditioning regimen is safe for elderly multiple myeloma patients
    Czyz, Anna
    Szeremet, Agnieszka
    Bogucka-Fedorczuk, Aleksandra
    Majcherek, Maciej
    Rybka, Justyna
    Prajs, Iwona
    Wrobel, Tomasz
    BONE MARROW TRANSPLANTATION, 2019, 54 : 499 - 500
  • [30] Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib
    Aypar, Eda
    Izzettin, Fikret Vehbi
    Aki, Sahika Zeynep
    Sancar, Mesut
    Yegin, Zeynep Arzu
    Turkoz-Sucak, Gulsan
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (04) : 281 - 289
12345